Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q8TE49

UPID:
OTU7A_HUMAN

ALTERNATIVE NAMES:
Zinc finger protein Cezanne 2

ALTERNATIVE UPACC:
Q8TE49; Q8IWK5

BACKGROUND:
The protein OTU domain-containing protein 7A, with alternative names such as Zinc finger protein Cezanne 2, is recognized for its deubiquitinating activity on 'Lys-11'-linked polyubiquitin chains. This specific activity is critical for the proper functioning of ubiquitin-mediated cellular signaling, impacting various biological processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of OTU domain-containing protein 7A holds the potential to unlock new therapeutic avenues. By targeting its deubiquitinating activity, novel treatments for diseases with underlying dysregulation of ubiquitin signaling could be developed.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.